Versant Vantage II GP-GP, LLC

SEC source: 0001209191-23-043527 · doc4.xml · derivative · entry 18

Versant Ventures V, LLC · CIK 0001619298 · 10% owner

Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner

Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner

Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner

Versant Ventures V GP-GP (Canada), Inc. · CIK 0001619297 · 10% owner

Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner

Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner

Versant Vantage II GP-GP, LLC · CIK 0001839789 · 10% owner

Versant Vantage II GP, L.P. · CIK 0001839790 · 10% owner

Versant Vantage II, L.P. · CIK 0001832235 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Versant Venture Capital V, L.P.

Disclosed balance after: 0

Underlying: Common Stock · 957,787 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date.

F1 · derivative.exercise_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date.

F1 · derivative.expiration_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date.

F2 · ownership.nature: Shares are held by Versant Venture Capital V, L.P. ("Versant V"). Versant Ventures V, LLC ("Versant V GP") is the sole general partner of Versant V. Jerel C. Davis is a managing director of Versant V GP and may be deemed to share voting and dispositive power over the shares held by Versant V. Each of the Reporting Persons disclaims beneficial ownership of the shares held by Versant V, except to the extent of its respective pecuniary interest therein. Dr. Davis is a director of the Issuer and files separate Section 16 reports.

SEC source: 0001209191-23-043527 · doc4.xml · derivative · entry 17

Versant Ventures V, LLC · CIK 0001619298 · 10% owner

Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner

Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner

Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner

Versant Ventures V GP-GP (Canada), Inc. · CIK 0001619297 · 10% owner

Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner

Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner

Versant Vantage II GP-GP, LLC · CIK 0001839789 · 10% owner

Versant Vantage II GP, L.P. · CIK 0001839790 · 10% owner

Versant Vantage II, L.P. · CIK 0001832235 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Versant Affiliates Fund V, L.P.

Disclosed balance after: 0

Underlying: Common Stock · 13,297 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date.

F1 · derivative.exercise_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date.

F1 · derivative.expiration_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date.

F5 · ownership.nature: Shares are held by Versant Affiliates Fund V, L.P. ("Affiliates V"). Versant V GP is the sole general partner of Affiliates V. Jerel C. Davis is a managing director of Versant V GP and may be deemed to share voting and dispositive power over the shares held by Affiliates V. Each of the Reporting Persons disclaims beneficial ownership of the shares held by Affiliates, except to the extent of its respective pecuniary interest therein. Dr. Davis is a director of the Issuer and files separate Section 16 reports.

SEC source: 0001209191-23-043527 · doc4.xml · derivative · entry 16

Versant Ventures V, LLC · CIK 0001619298 · 10% owner

Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner

Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner

Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner

Versant Ventures V GP-GP (Canada), Inc. · CIK 0001619297 · 10% owner

Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner

Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner

Versant Vantage II GP-GP, LLC · CIK 0001839789 · 10% owner

Versant Vantage II GP, L.P. · CIK 0001839790 · 10% owner

Versant Vantage II, L.P. · CIK 0001832235 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Versant Ophthalmic Affiliates Fund I, L.P.

Disclosed balance after: 0

Underlying: Common Stock · 14,739 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date.

F1 · derivative.exercise_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date.

F1 · derivative.expiration_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date.

F4 · ownership.nature: Shares are held by Versant Ophthalmic Affiliates Fund I, L.P. ("Ophthalmic"). Versant V GP is the sole general partner of Ophthalmic. Jerel C. Davis is a managing director of Versant V GP and may be deemed to share voting and dispositive power over the shares held by Ophthalmic. Each of the Reporting Persons disclaims beneficial ownership of the shares held by Ophthalmic, except to the extent of its respective pecuniary interest therein. Dr. Davis is a director of the Issuer and files separate Section 16 reports.

SEC source: 0001209191-23-043527 · doc4.xml · derivative · entry 15

Versant Ventures V, LLC · CIK 0001619298 · 10% owner

Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner

Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner

Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner

Versant Ventures V GP-GP (Canada), Inc. · CIK 0001619297 · 10% owner

Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner

Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner

Versant Vantage II GP-GP, LLC · CIK 0001839789 · 10% owner

Versant Vantage II GP, L.P. · CIK 0001839790 · 10% owner

Versant Vantage II, L.P. · CIK 0001832235 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Versant Venture Capital V (Canada) LP

Disclosed balance after: 0

Underlying: Common Stock · 33,642 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date.

F1 · derivative.exercise_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date.

F1 · derivative.expiration_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date.

F3 · ownership.nature: Shares are held by Versant Venture Capital V (Canada) LP ("Canada V"). Versant Ventures V (Canada), L.P. ("Canada V GP") is the general partner of Canada V and Versant Ventures V GP-GP (Canada), Inc. ("Canada V GP-GP") is the sole general partner of Canada V GP. Jerel C. Davis is a director of Canada V GP-GP and may be deemed to share voting and dispositive power over the shares held by Canada V. Each of the Reporting Persons disclaims beneficial ownership of the shares held by Canada V, except to the extent of its respective pecuniary interest therein. Dr. Davis is a director of the Issuer and files separate Section 16 reports.

SEC source: 0001209191-23-043527 · doc4.xml · derivative · entry 14

Versant Ventures V, LLC · CIK 0001619298 · 10% owner

Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner

Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner

Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner

Versant Ventures V GP-GP (Canada), Inc. · CIK 0001619297 · 10% owner

Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner

Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner

Versant Vantage II GP-GP, LLC · CIK 0001839789 · 10% owner

Versant Vantage II GP, L.P. · CIK 0001839790 · 10% owner

Versant Vantage II, L.P. · CIK 0001832235 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Versant Venture Capital V, L.P.

Disclosed balance after: 0

Underlying: Common Stock · 442,055 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date.

F1 · derivative.exercise_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date.

F1 · derivative.expiration_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date.

F2 · ownership.nature: Shares are held by Versant Venture Capital V, L.P. ("Versant V"). Versant Ventures V, LLC ("Versant V GP") is the sole general partner of Versant V. Jerel C. Davis is a managing director of Versant V GP and may be deemed to share voting and dispositive power over the shares held by Versant V. Each of the Reporting Persons disclaims beneficial ownership of the shares held by Versant V, except to the extent of its respective pecuniary interest therein. Dr. Davis is a director of the Issuer and files separate Section 16 reports.

SEC source: 0001209191-23-043527 · doc4.xml · derivative · entry 13

Versant Ventures V, LLC · CIK 0001619298 · 10% owner

Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner

Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner

Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner

Versant Ventures V GP-GP (Canada), Inc. · CIK 0001619297 · 10% owner

Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner

Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner

Versant Vantage II GP-GP, LLC · CIK 0001839789 · 10% owner

Versant Vantage II GP, L.P. · CIK 0001839790 · 10% owner

Versant Vantage II, L.P. · CIK 0001832235 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Versant Affiliates Fund V, L.P.

Disclosed balance after: 0

Underlying: Common Stock · 29,744 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date.

F1 · derivative.exercise_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date.

F1 · derivative.expiration_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date.

F5 · ownership.nature: Shares are held by Versant Affiliates Fund V, L.P. ("Affiliates V"). Versant V GP is the sole general partner of Affiliates V. Jerel C. Davis is a managing director of Versant V GP and may be deemed to share voting and dispositive power over the shares held by Affiliates V. Each of the Reporting Persons disclaims beneficial ownership of the shares held by Affiliates, except to the extent of its respective pecuniary interest therein. Dr. Davis is a director of the Issuer and files separate Section 16 reports.

SEC source: 0001209191-23-043527 · doc4.xml · derivative · entry 12

Versant Ventures V, LLC · CIK 0001619298 · 10% owner

Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner

Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner

Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner

Versant Ventures V GP-GP (Canada), Inc. · CIK 0001619297 · 10% owner

Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner

Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner

Versant Vantage II GP-GP, LLC · CIK 0001839789 · 10% owner

Versant Vantage II GP, L.P. · CIK 0001839790 · 10% owner

Versant Vantage II, L.P. · CIK 0001832235 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Versant Ophthalmic Affiliates Fund I, L.P.

Disclosed balance after: 0

Underlying: Common Stock · 32,971 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date.

F1 · derivative.exercise_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date.

F1 · derivative.expiration_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date.

F4 · ownership.nature: Shares are held by Versant Ophthalmic Affiliates Fund I, L.P. ("Ophthalmic"). Versant V GP is the sole general partner of Ophthalmic. Jerel C. Davis is a managing director of Versant V GP and may be deemed to share voting and dispositive power over the shares held by Ophthalmic. Each of the Reporting Persons disclaims beneficial ownership of the shares held by Ophthalmic, except to the extent of its respective pecuniary interest therein. Dr. Davis is a director of the Issuer and files separate Section 16 reports.

SEC source: 0001209191-23-043527 · doc4.xml · derivative · entry 11

Versant Ventures V, LLC · CIK 0001619298 · 10% owner

Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner

Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner

Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner

Versant Ventures V GP-GP (Canada), Inc. · CIK 0001619297 · 10% owner

Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner

Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner

Versant Vantage II GP-GP, LLC · CIK 0001839789 · 10% owner

Versant Vantage II GP, L.P. · CIK 0001839790 · 10% owner

Versant Vantage II, L.P. · CIK 0001832235 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Versant Venture Capital V (Canada) LP

Disclosed balance after: 0

Underlying: Common Stock · 75,255 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date.

F1 · derivative.exercise_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date.

F1 · derivative.expiration_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date.

F3 · ownership.nature: Shares are held by Versant Venture Capital V (Canada) LP ("Canada V"). Versant Ventures V (Canada), L.P. ("Canada V GP") is the general partner of Canada V and Versant Ventures V GP-GP (Canada), Inc. ("Canada V GP-GP") is the sole general partner of Canada V GP. Jerel C. Davis is a director of Canada V GP-GP and may be deemed to share voting and dispositive power over the shares held by Canada V. Each of the Reporting Persons disclaims beneficial ownership of the shares held by Canada V, except to the extent of its respective pecuniary interest therein. Dr. Davis is a director of the Issuer and files separate Section 16 reports.

SEC source: 0001209191-23-043527 · doc4.xml · derivative · entry 10

Versant Ventures V, LLC · CIK 0001619298 · 10% owner

Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner

Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner

Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner

Versant Ventures V GP-GP (Canada), Inc. · CIK 0001619297 · 10% owner

Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner

Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner

Versant Vantage II GP-GP, LLC · CIK 0001839789 · 10% owner

Versant Vantage II GP, L.P. · CIK 0001839790 · 10% owner

Versant Vantage II, L.P. · CIK 0001832235 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Versant Venture Capital V, L.P.

Disclosed balance after: 0

Underlying: Common Stock · 988,832 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date.

F1 · derivative.exercise_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date.

F1 · derivative.expiration_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date.

F2 · ownership.nature: Shares are held by Versant Venture Capital V, L.P. ("Versant V"). Versant Ventures V, LLC ("Versant V GP") is the sole general partner of Versant V. Jerel C. Davis is a managing director of Versant V GP and may be deemed to share voting and dispositive power over the shares held by Versant V. Each of the Reporting Persons disclaims beneficial ownership of the shares held by Versant V, except to the extent of its respective pecuniary interest therein. Dr. Davis is a director of the Issuer and files separate Section 16 reports.

SEC source: 0001209191-23-043527 · doc4.xml · nonDerivative · entry 9

Versant Ventures V, LLC · CIK 0001619298 · 10% owner

Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner

Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner

Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner

Versant Ventures V GP-GP (Canada), Inc. · CIK 0001619297 · 10% owner

Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner

Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner

Versant Vantage II GP-GP, LLC · CIK 0001839789 · 10% owner

Versant Vantage II GP, L.P. · CIK 0001839790 · 10% owner

Versant Vantage II, L.P. · CIK 0001832235 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Versant Affiliates Fund V, L.P.

Disclosed balance after: 82,006

F5 · ownership.nature: Shares are held by Versant Affiliates Fund V, L.P. ("Affiliates V"). Versant V GP is the sole general partner of Affiliates V. Jerel C. Davis is a managing director of Versant V GP and may be deemed to share voting and dispositive power over the shares held by Affiliates V. Each of the Reporting Persons disclaims beneficial ownership of the shares held by Affiliates, except to the extent of its respective pecuniary interest therein. Dr. Davis is a director of the Issuer and files separate Section 16 reports.

SEC source: 0001209191-23-043527 · doc4.xml · nonDerivative · entry 8

Versant Ventures V, LLC · CIK 0001619298 · 10% owner

Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner

Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner

Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner

Versant Ventures V GP-GP (Canada), Inc. · CIK 0001619297 · 10% owner

Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner

Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner

Versant Vantage II GP-GP, LLC · CIK 0001839789 · 10% owner

Versant Vantage II GP, L.P. · CIK 0001839790 · 10% owner

Versant Vantage II, L.P. · CIK 0001832235 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Versant Ophthalmic Affiliates Fund I, L.P.

Disclosed balance after: 90,888

F4 · ownership.nature: Shares are held by Versant Ophthalmic Affiliates Fund I, L.P. ("Ophthalmic"). Versant V GP is the sole general partner of Ophthalmic. Jerel C. Davis is a managing director of Versant V GP and may be deemed to share voting and dispositive power over the shares held by Ophthalmic. Each of the Reporting Persons disclaims beneficial ownership of the shares held by Ophthalmic, except to the extent of its respective pecuniary interest therein. Dr. Davis is a director of the Issuer and files separate Section 16 reports.

SEC source: 0001209191-23-043527 · doc4.xml · nonDerivative · entry 7

Versant Ventures V, LLC · CIK 0001619298 · 10% owner

Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner

Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner

Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner

Versant Ventures V GP-GP (Canada), Inc. · CIK 0001619297 · 10% owner

Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner

Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner

Versant Vantage II GP-GP, LLC · CIK 0001839789 · 10% owner

Versant Vantage II GP, L.P. · CIK 0001839790 · 10% owner

Versant Vantage II, L.P. · CIK 0001832235 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Versant Venture Capital V (Canada) LP

Disclosed balance after: 207,486

F3 · ownership.nature: Shares are held by Versant Venture Capital V (Canada) LP ("Canada V"). Versant Ventures V (Canada), L.P. ("Canada V GP") is the general partner of Canada V and Versant Ventures V GP-GP (Canada), Inc. ("Canada V GP-GP") is the sole general partner of Canada V GP. Jerel C. Davis is a director of Canada V GP-GP and may be deemed to share voting and dispositive power over the shares held by Canada V. Each of the Reporting Persons disclaims beneficial ownership of the shares held by Canada V, except to the extent of its respective pecuniary interest therein. Dr. Davis is a director of the Issuer and files separate Section 16 reports.

SEC source: 0001209191-23-043527 · doc4.xml · nonDerivative · entry 6

Versant Ventures V, LLC · CIK 0001619298 · 10% owner

Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner

Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner

Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner

Versant Ventures V GP-GP (Canada), Inc. · CIK 0001619297 · 10% owner

Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner

Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner

Versant Vantage II GP-GP, LLC · CIK 0001839789 · 10% owner

Versant Vantage II GP, L.P. · CIK 0001839790 · 10% owner

Versant Vantage II, L.P. · CIK 0001832235 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Versant Venture Capital V, L.P.

Disclosed balance after: 2,726,322

F2 · ownership.nature: Shares are held by Versant Venture Capital V, L.P. ("Versant V"). Versant Ventures V, LLC ("Versant V GP") is the sole general partner of Versant V. Jerel C. Davis is a managing director of Versant V GP and may be deemed to share voting and dispositive power over the shares held by Versant V. Each of the Reporting Persons disclaims beneficial ownership of the shares held by Versant V, except to the extent of its respective pecuniary interest therein. Dr. Davis is a director of the Issuer and files separate Section 16 reports.

SEC source: 0001209191-23-043527 · doc4.xml · nonDerivative · entry 5

Versant Ventures V, LLC · CIK 0001619298 · 10% owner

Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner

Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner

Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner

Versant Ventures V GP-GP (Canada), Inc. · CIK 0001619297 · 10% owner

Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner

Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner

Versant Vantage II GP-GP, LLC · CIK 0001839789 · 10% owner

Versant Vantage II GP, L.P. · CIK 0001839790 · 10% owner

Versant Vantage II, L.P. · CIK 0001832235 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Versant Vantage II, L.P.

Disclosed balance after: 274,990

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date.

F6 · ownership.nature: Shares held by Versant Vantage II, L.P. ("Vantage II"). Versant Vantage II GP, L.P. ("Vantage II GP") is the sole general partner of Vantage II and Versant Vantage II GP-GP, LLC (Vantage II GP-GP") is the sole general partner of Vantage II GP. Jerel C. Davis is a managing director of Vantage II GP-GP and may be deemed to share voting and dispositive power over the shares held by Vantage II. Each of the Reporting Persons disclaims beneficial ownership of the shares held by Canada V, except to the extent of its respective pecuniary interest therein. Dr. Davis is a director of the Issuer and files separate Section 16 reports.

SEC source: 0001209191-23-043527 · doc4.xml · nonDerivative · entry 4

Versant Ventures V, LLC · CIK 0001619298 · 10% owner

Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner

Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner

Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner

Versant Ventures V GP-GP (Canada), Inc. · CIK 0001619297 · 10% owner

Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner

Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner

Versant Vantage II GP-GP, LLC · CIK 0001839789 · 10% owner

Versant Vantage II GP, L.P. · CIK 0001839790 · 10% owner

Versant Vantage II, L.P. · CIK 0001832235 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Versant Affiliates Fund V, L.P.

Disclosed balance after: 76,067

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date.

F5 · ownership.nature: Shares are held by Versant Affiliates Fund V, L.P. ("Affiliates V"). Versant V GP is the sole general partner of Affiliates V. Jerel C. Davis is a managing director of Versant V GP and may be deemed to share voting and dispositive power over the shares held by Affiliates V. Each of the Reporting Persons disclaims beneficial ownership of the shares held by Affiliates, except to the extent of its respective pecuniary interest therein. Dr. Davis is a director of the Issuer and files separate Section 16 reports.

SEC source: 0001209191-23-043527 · doc4.xml · nonDerivative · entry 3

Versant Ventures V, LLC · CIK 0001619298 · 10% owner

Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner

Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner

Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner

Versant Ventures V GP-GP (Canada), Inc. · CIK 0001619297 · 10% owner

Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner

Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner

Versant Vantage II GP-GP, LLC · CIK 0001839789 · 10% owner

Versant Vantage II GP, L.P. · CIK 0001839790 · 10% owner

Versant Vantage II, L.P. · CIK 0001832235 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Versant Ophthalmic Affiliates Fund I, L.P.

Disclosed balance after: 84,313

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date.

F4 · ownership.nature: Shares are held by Versant Ophthalmic Affiliates Fund I, L.P. ("Ophthalmic"). Versant V GP is the sole general partner of Ophthalmic. Jerel C. Davis is a managing director of Versant V GP and may be deemed to share voting and dispositive power over the shares held by Ophthalmic. Each of the Reporting Persons disclaims beneficial ownership of the shares held by Ophthalmic, except to the extent of its respective pecuniary interest therein. Dr. Davis is a director of the Issuer and files separate Section 16 reports.

SEC source: 0001209191-23-043527 · doc4.xml · nonDerivative · entry 2

Versant Ventures V, LLC · CIK 0001619298 · 10% owner

Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner

Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner

Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner

Versant Ventures V GP-GP (Canada), Inc. · CIK 0001619297 · 10% owner

Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner

Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner

Versant Vantage II GP-GP, LLC · CIK 0001839789 · 10% owner

Versant Vantage II GP, L.P. · CIK 0001839790 · 10% owner

Versant Vantage II, L.P. · CIK 0001832235 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Versant Venture Capital V (Canada) LP

Disclosed balance after: 192,458

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date.

F3 · ownership.nature: Shares are held by Versant Venture Capital V (Canada) LP ("Canada V"). Versant Ventures V (Canada), L.P. ("Canada V GP") is the general partner of Canada V and Versant Ventures V GP-GP (Canada), Inc. ("Canada V GP-GP") is the sole general partner of Canada V GP. Jerel C. Davis is a director of Canada V GP-GP and may be deemed to share voting and dispositive power over the shares held by Canada V. Each of the Reporting Persons disclaims beneficial ownership of the shares held by Canada V, except to the extent of its respective pecuniary interest therein. Dr. Davis is a director of the Issuer and files separate Section 16 reports.

SEC source: 0001209191-23-043527 · doc4.xml · nonDerivative · entry 1

Versant Ventures V, LLC · CIK 0001619298 · 10% owner

Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner

Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner

Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner

Versant Ventures V GP-GP (Canada), Inc. · CIK 0001619297 · 10% owner

Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner

Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner

Versant Vantage II GP-GP, LLC · CIK 0001839789 · 10% owner

Versant Vantage II GP, L.P. · CIK 0001839790 · 10% owner

Versant Vantage II, L.P. · CIK 0001832235 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Versant Venture Capital V, L.P.

Disclosed balance after: 2,528,864

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date.

F2 · ownership.nature: Shares are held by Versant Venture Capital V, L.P. ("Versant V"). Versant Ventures V, LLC ("Versant V GP") is the sole general partner of Versant V. Jerel C. Davis is a managing director of Versant V GP and may be deemed to share voting and dispositive power over the shares held by Versant V. Each of the Reporting Persons disclaims beneficial ownership of the shares held by Versant V, except to the extent of its respective pecuniary interest therein. Dr. Davis is a director of the Issuer and files separate Section 16 reports.

SEC source: 0000899243-22-028388 · doc4.xml · nonDerivative · entry 2

Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner

Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner

Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner

Versant Vantage II, L.P. · CIK 0001832235 · 10% owner

Versant Vantage II GP, L.P. · CIK 0001839790 · 10% owner

Versant Vantage II GP-GP, LLC · CIK 0001839789 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,452,014

F4 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant VI to its limited partners pursuant to a Rule 10b5-1 trading plan.

F3 · ownership.direct: The reportable securities are owned directly by Versant VI. Versant Ventures VI GP, L.P. ("Versant Ventures VI GP") is the general partner of Versant VI, and Versant Ventures VI GP-GP, LLC ("Versant Ventures VI GP-GP") is the general partner of Versant Ventures VI GP. Each of Versant Ventures VI GP and Versant Ventures VI GP-GP may be deemed to indirectly beneficially own the shares beneficially owned by Versant VI, but disclaim beneficial ownership except to the extent of their pecuniary interest therein.

SEC source: 0000899243-22-028388 · doc4.xml · nonDerivative · entry 1

Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner

Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner

Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner

Versant Vantage II, L.P. · CIK 0001832235 · 10% owner

Versant Vantage II GP, L.P. · CIK 0001839790 · 10% owner

Versant Vantage II GP-GP, LLC · CIK 0001839789 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,816,814

F1 · kind: The sale of these shares was effected pursuant to a Rule 10b5-1 trading plan adopted by Versant Venture Capital VI, L.P. ("Versant VI").

F2 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $13.03 to $13.26, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.

F3 · ownership.direct: The reportable securities are owned directly by Versant VI. Versant Ventures VI GP, L.P. ("Versant Ventures VI GP") is the general partner of Versant VI, and Versant Ventures VI GP-GP, LLC ("Versant Ventures VI GP-GP") is the general partner of Versant Ventures VI GP. Each of Versant Ventures VI GP and Versant Ventures VI GP-GP may be deemed to indirectly beneficially own the shares beneficially owned by Versant VI, but disclaim beneficial ownership except to the extent of their pecuniary interest therein.

SEC source: 0000899243-22-004169 · doc4.xml · nonDerivative · entry 1

Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner

Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner

Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner

Versant Vantage II, L.P. · CIK 0001832235 · 10% owner

Versant Vantage II GP, L.P. · CIK 0001839790 · 10% owner

Versant Vantage II GP-GP, LLC · CIK 0001839789 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,366,814

F1 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Venture Capital VI, L.P. ("Versant VI") to its limited partners.

F2 · ownership.direct: The reportable securities are owned directly by Versant VI. Versant Ventures VI GP, L.P. ("Versant Ventures VI GP") is the general partner of Versant VI, and Versant Ventures VI GP-GP, LLC ("Versant Ventures VI GP-GP") is the general partner of Versant Ventures VI GP. Versant Ventures VI GP and Versant Ventures VI GP-GP may be deemed to indirectly beneficially own the shares beneficially owned by Versant VI, but disclaim beneficial ownership except to the extent of their pecuniary interest therein.

SEC source: 0000899243-21-049938 · doc4.xml · nonDerivative · entry 1

Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner

Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner

Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner

Versant Vantage II, L.P. · CIK 0001832235 · 10% owner

Versant Vantage II GP, L.P. · CIK 0001839790 · 10% owner

Versant Vantage II GP-GP, LLC · CIK 0001839789 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,545,810

F1 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Venture Capital VI, L.P. ("Versant VI") to its limited partners pursuant to a Rule 10b5-1 trading plan.

F2 · ownership.direct: The reportable securities are owned directly by Versant VI. Versant Ventures VI GP, L.P. ("Versant Ventures VI GP") is the general partner of Versant VI, and Versant Ventures VI GP-GP, LLC ("Versant Ventures VI GP-GP") is the general partner of Versant Ventures VI GP. Versant Ventures VI GP and Versant Ventures VI GP-GP may be deemed to indirectly beneficially own the shares beneficially owned by Versant VI, but disclaim beneficial ownership except to the extent of their pecuniary interest therein.

SEC source: 0000899243-21-027018 · doc4.xml · derivative · entry 5

Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner

Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner

Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner

Versant Vantage II, L.P. · CIK 0001832235 · 10% owner

Versant Vantage II GP, L.P. · CIK 0001839790 · 10% owner

Versant Vantage II GP-GP, LLC · CIK 0001839789 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Stock · 1,527,719 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: These shares of the Series B Preferred Stock were convertible at any time at the holder's election and automatically converted on a 2.432-for-one basis into shares of the Issuer's common stock into shares of the Issuer's common stock immediately upon the closing of the IPO without payment of additional consideration. The Series B Preferred Stock had no expiration date.

F3 · price: These shares of the Series B Preferred Stock were convertible at any time at the holder's election and automatically converted on a 2.432-for-one basis into shares of the Issuer's common stock into shares of the Issuer's common stock immediately upon the closing of the IPO without payment of additional consideration. The Series B Preferred Stock had no expiration date.

F3 · derivative.exercise_date: These shares of the Series B Preferred Stock were convertible at any time at the holder's election and automatically converted on a 2.432-for-one basis into shares of the Issuer's common stock into shares of the Issuer's common stock immediately upon the closing of the IPO without payment of additional consideration. The Series B Preferred Stock had no expiration date.

F3 · derivative.expiration_date: These shares of the Series B Preferred Stock were convertible at any time at the holder's election and automatically converted on a 2.432-for-one basis into shares of the Issuer's common stock into shares of the Issuer's common stock immediately upon the closing of the IPO without payment of additional consideration. The Series B Preferred Stock had no expiration date.

F4 · ownership.nature: These shares are held by Versant Vantage II, L.P. ("VV II"). Versant Vantage II GP-GP, LLC ("VV II GP-GP") is the sole general partner of Versant Vantage II GP, L.P. ("VV II GP") and VV II GP is the sole general partner of VV II. Jerel C. Davis, a member of the Issuer's board of directors, is a managing member of VV II GP-GP and may be deemed to share voting and dispositive power over the shares held by VV II. Each of VV II GP-GP, VV II GP and Jerel C. Davis disclaims beneficial ownership of the shares held by VV II, except to the extent of their respective pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly files separate Section 16 reports.

SEC source: 0000899243-21-027018 · doc4.xml · derivative · entry 4

Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner

Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner

Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner

Versant Vantage II, L.P. · CIK 0001832235 · 10% owner

Versant Vantage II GP, L.P. · CIK 0001839790 · 10% owner

Versant Vantage II GP-GP, LLC · CIK 0001839789 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 12,343,727 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: These shares of the Series A Preferred Stock were convertible at any time at the holder's election and automatically converted on a 2.432-for-one basis into shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering ("IPO") without payment of additional consideration. The Series A Preferred Stock had no expiration date.

F1 · price: These shares of the Series A Preferred Stock were convertible at any time at the holder's election and automatically converted on a 2.432-for-one basis into shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering ("IPO") without payment of additional consideration. The Series A Preferred Stock had no expiration date.

F1 · derivative.exercise_date: These shares of the Series A Preferred Stock were convertible at any time at the holder's election and automatically converted on a 2.432-for-one basis into shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering ("IPO") without payment of additional consideration. The Series A Preferred Stock had no expiration date.

F1 · derivative.expiration_date: These shares of the Series A Preferred Stock were convertible at any time at the holder's election and automatically converted on a 2.432-for-one basis into shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering ("IPO") without payment of additional consideration. The Series A Preferred Stock had no expiration date.

F2 · ownership.direct: These shares are held by Versant Venture Capital VI, L.P. ("VVC VI"). Versant Ventures VI GP-GP, LLC ("VV VI GP") is the sole general partner of Versant Ventures VI GP, L.P. ("VV VI") and VV VI is the sole general partner of VVC VI. Jerel C. Davis, a member of the Issuer's board of directors, is a managing member of VV VI GP and may be deemed to share voting and dispositive power over the shares held by VVC VI. Each of VV VI GP, VV VI and Jerel C. Davis disclaims beneficial ownership of the shares held by VVC VI, except to the extent of their respective pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly files separate Section 16 reports.

SEC source: 0000899243-21-027018 · doc4.xml · nonDerivative · entry 3

Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner

Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner

Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner

Versant Vantage II, L.P. · CIK 0001832235 · 10% owner

Versant Vantage II GP, L.P. · CIK 0001839790 · 10% owner

Versant Vantage II GP-GP, LLC · CIK 0001839789 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 1,707,719

F4 · ownership.nature: These shares are held by Versant Vantage II, L.P. ("VV II"). Versant Vantage II GP-GP, LLC ("VV II GP-GP") is the sole general partner of Versant Vantage II GP, L.P. ("VV II GP") and VV II GP is the sole general partner of VV II. Jerel C. Davis, a member of the Issuer's board of directors, is a managing member of VV II GP-GP and may be deemed to share voting and dispositive power over the shares held by VV II. Each of VV II GP-GP, VV II GP and Jerel C. Davis disclaims beneficial ownership of the shares held by VV II, except to the extent of their respective pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly files separate Section 16 reports.

SEC source: 0000899243-21-027018 · doc4.xml · nonDerivative · entry 2

Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner

Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner

Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner

Versant Vantage II, L.P. · CIK 0001832235 · 10% owner

Versant Vantage II GP, L.P. · CIK 0001839790 · 10% owner

Versant Vantage II GP-GP, LLC · CIK 0001839789 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 1,527,719

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · price: These shares of the Series B Preferred Stock were convertible at any time at the holder's election and automatically converted on a 2.432-for-one basis into shares of the Issuer's common stock into shares of the Issuer's common stock immediately upon the closing of the IPO without payment of additional consideration. The Series B Preferred Stock had no expiration date.

F4 · ownership.nature: These shares are held by Versant Vantage II, L.P. ("VV II"). Versant Vantage II GP-GP, LLC ("VV II GP-GP") is the sole general partner of Versant Vantage II GP, L.P. ("VV II GP") and VV II GP is the sole general partner of VV II. Jerel C. Davis, a member of the Issuer's board of directors, is a managing member of VV II GP-GP and may be deemed to share voting and dispositive power over the shares held by VV II. Each of VV II GP-GP, VV II GP and Jerel C. Davis disclaims beneficial ownership of the shares held by VV II, except to the extent of their respective pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly files separate Section 16 reports.

SEC source: 0000899243-21-027018 · doc4.xml · nonDerivative · entry 1

Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner

Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner

Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner

Versant Vantage II, L.P. · CIK 0001832235 · 10% owner

Versant Vantage II GP, L.P. · CIK 0001839790 · 10% owner

Versant Vantage II GP-GP, LLC · CIK 0001839789 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,708,398

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: These shares of the Series A Preferred Stock were convertible at any time at the holder's election and automatically converted on a 2.432-for-one basis into shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering ("IPO") without payment of additional consideration. The Series A Preferred Stock had no expiration date.

F2 · ownership.direct: These shares are held by Versant Venture Capital VI, L.P. ("VVC VI"). Versant Ventures VI GP-GP, LLC ("VV VI GP") is the sole general partner of Versant Ventures VI GP, L.P. ("VV VI") and VV VI is the sole general partner of VVC VI. Jerel C. Davis, a member of the Issuer's board of directors, is a managing member of VV VI GP and may be deemed to share voting and dispositive power over the shares held by VVC VI. Each of VV VI GP, VV VI and Jerel C. Davis disclaims beneficial ownership of the shares held by VVC VI, except to the extent of their respective pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly files separate Section 16 reports.

SEC source: 0001104659-21-084643 · tm2120529-1_4seq1.xml · derivative · entry 5

Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner

Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner

Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner

Versant Vantage II, L.P. · CIK 0001832235 · 10% owner

Versant Vantage II GP, L.P. · CIK 0001839790 · 10% owner

Versant Vantage II GP-GP, LLC · CIK 0001839789 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Stock · 614,095 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Shares of Series C Preferred Stock automatically converted into shares of Common Stock at a 2.5161-for-1 conversion rate immediately prior to the closing of the Issuer's initial public offering and have no expiration date.

F3 · derivative.exercise_date: Shares of Series C Preferred Stock automatically converted into shares of Common Stock at a 2.5161-for-1 conversion rate immediately prior to the closing of the Issuer's initial public offering and have no expiration date.

F3 · derivative.expiration_date: Shares of Series C Preferred Stock automatically converted into shares of Common Stock at a 2.5161-for-1 conversion rate immediately prior to the closing of the Issuer's initial public offering and have no expiration date.

F3 · derivative.underlying_shares: Shares of Series C Preferred Stock automatically converted into shares of Common Stock at a 2.5161-for-1 conversion rate immediately prior to the closing of the Issuer's initial public offering and have no expiration date.

F4 · ownership.nature: The reportable securities are owned by Versant Vantage II, L.P. ("Versant Vantage II''). Versant Vantage II GP, L.P. ("Versant Vantage II GP") is the general partner of Versant Vantage II, and Versant Vantage II GP-GP, LLC ("Versant Vantage II GP-GP") is the general partner of Versant Vantage II GP. Versant Vantage II GP and Versant Vantage II GP-GP may be deemed to indirectly beneficially own the shares beneficially owned by Versant Vantage II, but disclaim beneficial ownership except to the extent of their pecuniary interest therein.

SEC source: 0001104659-21-084643 · tm2120529-1_4seq1.xml · derivative · entry 4

Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner

Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner

Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner

Versant Vantage II, L.P. · CIK 0001832235 · 10% owner

Versant Vantage II GP, L.P. · CIK 0001839790 · 10% owner

Versant Vantage II GP-GP, LLC · CIK 0001839789 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 9,936,011 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Shares of Series A Preferred Stock automatically converted into shares of Common Stock at a 2.5161-for-1 conversion rate immediately prior to the closing of the Issuer's initial public offering and have no expiration date.

F1 · derivative.exercise_date: Shares of Series A Preferred Stock automatically converted into shares of Common Stock at a 2.5161-for-1 conversion rate immediately prior to the closing of the Issuer's initial public offering and have no expiration date.

F1 · derivative.expiration_date: Shares of Series A Preferred Stock automatically converted into shares of Common Stock at a 2.5161-for-1 conversion rate immediately prior to the closing of the Issuer's initial public offering and have no expiration date.

F1 · derivative.underlying_shares: Shares of Series A Preferred Stock automatically converted into shares of Common Stock at a 2.5161-for-1 conversion rate immediately prior to the closing of the Issuer's initial public offering and have no expiration date.

F2 · ownership.direct: The reportable securities are owned directly by Versant Venture Capital VI, L.P. ("Versant VI"). Versant Ventures VI GP, L.P. ("Versant Ventures VI GP") is the general partner of Versant VI, and Versant Ventures VI GP-GP, LLC ("Versant Ventures VI GP-GP") is the general partner of Versant Ventures VI GP. Versant Ventures VI GP and Versant Ventures VI GP-GP may be deemed to indirectly beneficially own the shares beneficially owned by Versant VI, but disclaim beneficial ownership except to the extent of their pecuniary interest therein.

SEC source: 0001104659-21-084643 · tm2120529-1_4seq1.xml · nonDerivative · entry 3

Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner

Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner

Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner

Versant Vantage II, L.P. · CIK 0001832235 · 10% owner

Versant Vantage II GP, L.P. · CIK 0001839790 · 10% owner

Versant Vantage II GP-GP, LLC · CIK 0001839789 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 714,095

F4 · ownership.nature: The reportable securities are owned by Versant Vantage II, L.P. ("Versant Vantage II''). Versant Vantage II GP, L.P. ("Versant Vantage II GP") is the general partner of Versant Vantage II, and Versant Vantage II GP-GP, LLC ("Versant Vantage II GP-GP") is the general partner of Versant Vantage II GP. Versant Vantage II GP and Versant Vantage II GP-GP may be deemed to indirectly beneficially own the shares beneficially owned by Versant Vantage II, but disclaim beneficial ownership except to the extent of their pecuniary interest therein.

SEC source: 0001104659-21-084643 · tm2120529-1_4seq1.xml · nonDerivative · entry 2

Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner

Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner

Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner

Versant Vantage II, L.P. · CIK 0001832235 · 10% owner

Versant Vantage II GP, L.P. · CIK 0001839790 · 10% owner

Versant Vantage II GP-GP, LLC · CIK 0001839789 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 614,095

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · price: Shares of Series C Preferred Stock automatically converted into shares of Common Stock at a 2.5161-for-1 conversion rate immediately prior to the closing of the Issuer's initial public offering and have no expiration date.

F4 · ownership.nature: The reportable securities are owned by Versant Vantage II, L.P. ("Versant Vantage II''). Versant Vantage II GP, L.P. ("Versant Vantage II GP") is the general partner of Versant Vantage II, and Versant Vantage II GP-GP, LLC ("Versant Vantage II GP-GP") is the general partner of Versant Vantage II GP. Versant Vantage II GP and Versant Vantage II GP-GP may be deemed to indirectly beneficially own the shares beneficially owned by Versant Vantage II, but disclaim beneficial ownership except to the extent of their pecuniary interest therein.

SEC source: 0001104659-21-084643 · tm2120529-1_4seq1.xml · nonDerivative · entry 1

Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner

Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner

Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner

Versant Vantage II, L.P. · CIK 0001832235 · 10% owner

Versant Vantage II GP, L.P. · CIK 0001839790 · 10% owner

Versant Vantage II GP-GP, LLC · CIK 0001839789 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,916,814

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Shares of Series A Preferred Stock automatically converted into shares of Common Stock at a 2.5161-for-1 conversion rate immediately prior to the closing of the Issuer's initial public offering and have no expiration date.

F2 · ownership.direct: The reportable securities are owned directly by Versant Venture Capital VI, L.P. ("Versant VI"). Versant Ventures VI GP, L.P. ("Versant Ventures VI GP") is the general partner of Versant VI, and Versant Ventures VI GP-GP, LLC ("Versant Ventures VI GP-GP") is the general partner of Versant Ventures VI GP. Versant Ventures VI GP and Versant Ventures VI GP-GP may be deemed to indirectly beneficially own the shares beneficially owned by Versant VI, but disclaim beneficial ownership except to the extent of their pecuniary interest therein.